Home » Stocks » ATRS

Antares Pharma, Inc. (ATRS)

Stock Price: $4.28 USD -0.06 (-1.38%)
Updated Jan 15, 2021 4:00 PM EST - Market closed
After-hours: $4.32 +0.04 (0.94%) Jan 15, 6:59 PM
Market Cap 713.36M
Revenue (ttm) 143.31M
Net Income (ttm) 9.51M
Shares Out 166.38M
EPS (ttm) 0.06
PE Ratio 75.09
Forward PE 14.62
Dividend n/a
Dividend Yield n/a
Trading Day January 15
Last Price $4.28
Previous Close $4.34
Change ($) -0.06
Change (%) -1.38%
Day's Open 4.34
Day's Range 4.27 - 4.42
Day's Volume 1,047,748
52-Week Range 1.75 - 4.42

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
The Motley Fool - 3 weeks ago

These interesting low-cost stocks have the opportunity to grow.

Other stocks mentioned: FLNT, OPK
The Motley Fool - 1 month ago

These companies offer more potential than the stock price might indicate.

Other stocks mentioned: NOK, GSKY
GlobeNewsWire - 1 month ago

EWING, N.J., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a pharmaceutical technology company, today announced that Robert F. Apple, President and Chi...

GlobeNewsWire - 2 months ago

EWING, N.J., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a pharmaceutical technology company, today announced that Robert F. Apple, President and Chi...

Seeking Alpha - 2 months ago

Antares Pharma, Inc. (ATRS) CEO Bob Apple on Q3 2020 Results - Earnings Call Transcript

Other stocks mentioned: AAPL
Zacks Investment Research - 2 months ago

Antares Pharma (ATRS) delivered earnings and revenue surprises of 0.00% and 10.84%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 2 months ago

Antares Pharma (ATRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 2 months ago

EWING, N.J., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a pharmaceutical technology company, today announced it will release its third quarter 2020 ...

Seeking Alpha - 3 months ago

Since my last article in July, Antares has rallied over 20%, finally getting back to the lower end of where it was trading pre-COVID-19.

GlobeNewsWire - 3 months ago

Antares Expands Urology Portfolio and Leverages Commercial Organization Antares Expands Urology Portfolio and Leverages Commercial Organization

GlobeNewsWire - 4 months ago

EWING, N.J., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a pharmaceutical technology company, today announced that Robert F. Apple, President and ...

GlobeNewsWire - 5 months ago

Jack Howarth Retires as Vice President of Corporate Affairs Jack Howarth Retires as Vice President of Corporate Affairs

Seeking Alpha - 5 months ago

Antares Pharma, Inc. (ATRS) CEO Robert Apple on Q2 2020 Results - Earnings Call Transcript

Other stocks mentioned: AAPL
Benzinga - 5 months ago

Antares Pharma (NASDAQ: ATRS) shares are trading higher on Monday after the company announced a deal with Lunatus Global to distribute and promote XYOSTED in Saudi Arabia.

GlobeNewsWire - 5 months ago

EWING, N.J., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS), a pharmaceutical technology company, today announced they have entered into an exclusive distribution agre...

GlobeNewsWire - 5 months ago

EWING, N.J., July 21, 2020 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“Antares”) (“the Company”), a pharmaceutical technology company, announced the first commercialization of ...

GlobeNewsWire - 5 months ago

EWING, N.J., July 20, 2020 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a pharmaceutical technology company, today announced the appointment of Patrick Shea to th...

Seeking Alpha - 6 months ago

Antares Continues To Quietly Grow Revenue

GlobeNewsWire - 7 months ago

EWING, N.J., June 11, 2020 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), today announced that Robert F. Apple, President and Chief Executive Officer, will present ...

The Motley Fool - 7 months ago

Why is a fast-growing company making one of the best testosterone replacement therapies on the market so underappreciated by investors?

Seeking Alpha - 8 months ago

Antares Pharma, Inc. (ATRS) CEO Robert Apple on Q1 2020 Results - Earnings Call Transcript

Other stocks mentioned: AAPL
The Motley Fool - 8 months ago

First-quarter financial results failed to spark investors' animal spirits.

Seeking Alpha - 9 months ago

Antares Pharma: An Undervalued Stock To Buy During The COVID-19 Crisis

Seeking Alpha - 10 months ago

Antares Pharma, Inc. (ATRS) CEO Bob Apple on Q4 2019 Results - Earnings Call Transcript

Other stocks mentioned: AAPL
The Motley Fool - 10 months ago

Products from the pharmaceutical technology company continued to pick up momentum in the fourth quarter.

Seeking Alpha - 10 months ago

Antares Pharma: Reasonable Expectations For 2020

Seeking Alpha - 11 months ago

Antares Pharma: XYOSTED's Prescription Growth Is Running On All Cylinders

GlobeNewsWire - 11 months ago

The Company Expects 2019 Net Revenue at Upper End or Exceed Range of $115 - $120 Million Guidance The Company Expects 2019 Net Revenue at Upper End or Exceed Range of $115 - $120 Million Guidance

The Motley Fool - 1 year ago

Investors are locking in gains in this fast-growing drugmaker.

GlobeNewsWire - 1 year ago

EWING, N.J., Dec. 10, 2019 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) today announced the appointment of Edward Tykot to the position of Senior Vice President, Corporate Develop...

GlobeNewsWire - 1 year ago

EWING, N.J., Dec. 06, 2019 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“Antares”) (“the Company”) today announced that the Company’s social media campaign for XYOSTED®, has been...

Seeking Alpha - 1 year ago

Antares' Xyosted Is One Of The Best Testosterone Replacement Therapies Available

GlobeNewsWire - 1 year ago

Novel Drug Device Combination Product To Be Developed For The Treatment Of Suspected Acute Myocardial Infarction Novel Drug Device Combination Product To Be Developed For The Treatment Of Susp...

GlobeNewsWire - 1 year ago

Novel Drug Device Combination Product To Be Developed For The Treatment Of Suspected Acute Myocardial Infarction Novel Drug Device Combination Product To Be Developed For The Treatment Of Susp...

GlobeNewsWire - 1 year ago

EWING, N.J., Oct. 31, 2019 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“Antares” or “Company”) today announced that it has received the final payment of $2.5 million from Ferrin...

GlobeNewsWire - 1 year ago

EWING, N.J., Oct. 24, 2019 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) today announced that data from two poster presentations will be presented on Saturday October 26, 2019 at t...

GlobeNewsWire - 1 year ago

EWING, N.J., Sept. 17, 2019 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) today announced that Robert F. Apple, President and Chief Executive Officer, will present at the Ladenburg...

Seeking Alpha - 1 year ago

Every 1% of market share captured by XYOSTED in the testosterone replacement therapy market would grant ATRS $8.5 million in annual sales.

Seeking Alpha - 1 year ago

Since the approval of Clarus' TRT drug Jatenzo on March 28, Antares shares have been under pressure, breaking an upward trend to the downside.

Seeking Alpha - 1 year ago

Antares Pharma, Inc. (ATRS) CEO Bob Apple on Q1 2019 Results - Earnings Call Transcript

Seeking Alpha - 1 year ago

Regardless of the company’s growing, diversified portfolio and pipeline of drugs, Antares stock continues to trade like it is a one-product company.

About ATRS

Antares Pharma focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies in the United States, Europe, and internationally. The company's injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis (RA) and psoriasis patients to self-inject methotrexate at home; XYOSTED for the treatment of testosterone deficiency in adult males; Sumatriptan Injection USP for the acute treatment of migraine and cluster he... [Read more...]

Industry
Medical Instruments & Supplies
IPO Date
Oct 2, 1996
CEO
Robert Apple
Employees
178
Stock Exchange
NASDAQ
Ticker Symbol
ATRS
Full Company Profile

Financial Performance

In 2019, Antares Pharma's revenue was $123.86 million, an increase of 94.90% compared to the previous year's $63.55 million. Losses were -$2.03 million, -68.89% less than in 2018.

Financial Statements

Analyst Forecasts

According to 6 analysts, the average rating for Antares Pharma stock is "Strong Buy." The 12-month stock price forecast is 6.25, which is an increase of 46.03% from the latest price.

Price Target
$6.25
(46.03% upside)
Analyst Consensus: Strong Buy